Overview
 |
James B. Hermiller, MD, MSCAI
Moderator and Speaker |
 |
Molly Szerlip, MD, FSCAI
Moderator |
 |
David J. Cohen, MD, FSCAI
Speaker |
 |
Megan Coylewright, MD, FSCAI
Speaker |
  |
Sammy Elmariah, MD, FSCAI
Speaker |
 |
Philippe Genereux, MD, FSCAI
Speaker |
Welcome and Introductions, James B. Hermiller, MD, MSCAI
Patient Pathway Solutions: Results of the DETECT-AS Study, Sammy Elmariah, MD, FSCAI
Latest Evidence from the EARLY TAVR Trial: Treatment of Asymptomatic SAS Patients, Philippe Genereux, MD, FSCAI
Heart Teams and Referrers: How Can They Engage to Treat All SAS Patients and Address Capacity? David J. Cohen, MD, FSCAI
TAVR in Younger Patients: What About Durability? Megan Coylewright, MD, FSCAI
Acknowledgment of Commercial Support
This activity is supported by an unrestricted educational grant from Edwards Lifesciences.
Learning Objectives
Upon completion of this activity, participants will be able to:
1. Evaluate the findings of the DETECT-AS study and discuss how ECHO alert systems could improve guideline adherence and patient outcomes in severe aortic stenosis (SAS).
2. Analyze the results of the EARLY TAVR trial, including its implications for treating patients classified as asymptomatic and the concept of Acute Valve Syndrome in SAS.
3. Discuss strategies for increasing engagement between heart teams and referrers to ensure timely intervention for all SAS patients, considering capacity challenges and potential changes to national coverage determinations (NCDs).
4. Review durability concerns and data on valve performance over time to guide decision-making in younger SAS patients.
5. Identify key practice modifications, including the role of exercise testing, earlier referrals, and heart team collaboration, to optimize outcomes for SAS patients.
Continuing Education Information
Accreditation Statement
The Society for Cardiovascular Angiography and Interventions (SCAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation
SCAI designates this enduring material for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABIM MOC
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Successful Completion
Watch the content and complete the evaluation to obtain credit.
Activity Timeline
Record date: May 3, 2025
Publish date: June 18, 2025
Retire date: June 18, 2026
Disclosures
PLANNER
James Hermiller: Edwards Lifesciences - Consulting; Abbott - Consulting.
FACULTY
David Cohen, Sammy Elmariah: No financial relationships with ineligible companies.
Megan Coylewright: Edwards Lifesciences - Consulting. Boston Scientific Corp. - Advisory Board, Consulting.
Philippe Genereux: Edwards Lifesciences - Consulting
Molly Szerlip: Edwards Lifesciences - Speaker, Consulting, PI; Medtronic - PI; Boston Scientific Corp. - Advisory Board; Abbott - PI, Advisory Board.
REVIEWER
Binita Shah: No financial relationships with ineligible companies.
SCAI STAFF
Laura Porter: No financial relationships with ineligible companies
SCAI's Independent Content
As a provider of continuing medical education through the Accreditation Council for Continuing Medical Education (ACCME), it is the Society’s policy to ensure balance, independence, objectivity, and scientific rigor in all its activities.
Planning Process
SCAI activities are developed by the SCAI planners prior to and independent of commercial support. Members of the Education Committee reviewed and approved this activity. If planners had relevant financial relationships, the agenda was peer reviewed by a member with no relevant financial relationships.
Mitigation of Relevant Financial Relationships
All participating planners, reviewers, faculty, and staff are required to disclose to SCAI all financial relationships with ineligible companies. SCAI identifies relevant financial relationships and mitigates them before the activity begins.
Content Validation Statement
SCAI accepts the following Content Validation Statements and expects all persons involved in its professional education activities to abide by these statements for clinical care recommendations.
All clinical and pharmacological recommendations are based on evidence accepted within the medical profession as adequate jurisdiction for their indications and contradictions in patient care. SCAI does not promote recommendations, treatment, or manners of practicing medicine that are not within the definition of accredited continuing education or known to have risks or dangers that outweigh the benefits or known to be ineffective in the treatment of patients.
All research referenced to support or justify patient care recommendations conforms to accepted standards of experimental design, data collection and analysis.
SCAI actively promotes improvements in health care and NOT proprietary interests of an ineligible company. SCAI's educational content is free of marketing or sales of products or services.
Faculty will not actively promote or sell products or services that serve their professional or financial interests during accredited education.
SCAI encourages faculty to identify investigational products or off-label uses of products regulated by the U.S. Food and Drug Administration (FDA), at first mention and where appropriate in the content.
Copyright
© 2025 Society for Cardiovascular Angiography and Interventions (SCAI). All rights reserved.